Sign In
Buy CHMA
$3.76
+0 (+0%)
At Close: May 27, 2022
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
Chiasma to Report Second Quarter 2020 Results on August 10
08:01pm, Monday, 03'rd Aug 2020
Company to host conference call and webcast at 5:00 p.m. ETNEEDHAM, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced
\-- The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was
Were Hedge Funds Right About Chiasma Inc (CHMA)?
01:21am, Thursday, 09'th Jul 2020
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest
-$0.40 EPS Expected for Chiasma Inc (NASDAQ:CHMA) This Quarter
06:26am, Friday, 03'rd Jul 2020
Analysts predict that Chiasma Inc (NASDAQ:CHMA) will report earnings of ($0.40) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Chiasma’s earnings, with t
Why Chiasma’s Shares Are Down Today
03:53pm, Wednesday, 01'st Jul 2020
On Wednesday morning, Chiasma, Inc. (NASDAQ: CHMA) announced the pricing of a public offering of common stock and pre-funded warrants. Naturally, investors are not thrilled about the company's decisi
Chiasma Announces Pricing of a Public Offering of $70 Million of Common Stock and Pre-Funded Warrants
01:05pm, Wednesday, 01'st Jul 2020
Chiasma, Inc. (CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its proprietary Transient Permeability Enhancer (TPE®) delivery platfor
Is Chiasma (CHMA) Stock a Solid Choice Right Now?
12:55pm, Wednesday, 01'st Jul 2020
Chiasma (CHMA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
The Daily Biotech Pulse: T2 Biosystems Launches COVID-19 Test, Akero Aces Midstage NASH Study, Aravive Added to Russell Indexes
12:00am, Wednesday, 01'st Jul 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 30)
ADC Therapeutics SA (NYSE:...
Chiasma Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
08:30pm, Tuesday, 30'th Jun 2020
Chiasma, Inc. (CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its proprietary Transient Permeability Enhancer (TPE®) delivery platfor
Chiasma's Valuation Should Be Higher Than $5-6/Share Now That Mycapssa Is FDA Approved (NASDAQ:CHMA)
04:31pm, Tuesday, 30'th Jun 2020
On Friday, June 26, 2020, the FDA approved CHMA's Mycapssa. Shares fell on the news to reflect a market cap of ~$250MM and an enterprise valuation of less than
Chiasma's Valuation Should Be Higher Than $5-6/Share Now That Mycapssa Is FDA Approved
12:31pm, Tuesday, 30'th Jun 2020
On Friday, June 26, 2020, the FDA approved CHMA's Mycapssa. Shares fell on the news to reflect a market cap of ~$250MM and an enterprise valuation of less than
Are Options Traders Betting on a Big Move in Chiasma (CHMA) Stock?
01:52pm, Monday, 29'th Jun 2020
Investors need to pay close attention to Chiasma (CHMA) stock based on the movements in the options market lately.
Chiasma (CHMA) Gets a Buy Rating from H.C. Wainwright - Markets
10:19am, Monday, 29'th Jun 2020
H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Chiasma (CHMA – Research Report) today and set a price
Acceleron's Sotatercept Trial, And Other News: The Good, Bad And Ugly Of Biopharma
03:34pm, Sunday, 28'th Jun 2020
Acceleron's sotatercept phase 2 trial yields positive data. Insmed reports positive phase 2 data from the WILLOW study. Chiasma's Mycapssa capsules get FDA appr
